Royalty Pharma (RPRX) said Wednesday that it has agreed to provide Biogen (BIIB) with up to $250 million in research and development funding for drug candidate litifilimab to potentially treat systemic lupus erythematosus and cutaneous lupus erythematosus.
The company said it will provide the funding over six quarters in exchange for regulatory milestones and mid-single digit royalties on annual worldwide sales.
Litifilimab is currently in phase 3 trials, with results expected between 2026 and 2027, Royalty Pharma said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。